Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of CLN-978 (CD19XCD3XHSA) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Geoffrey P. Shouse, Kristie A. Blum, Julie E. Haydu, Jeremy S. Abramson, Mayur Narkhede, Andrew Ip, Jennifer S. Michaelson, Patrick A. Baeuerle, Kristan Meetze, Irina Shapiro, Todd Shearer, Judith Inumerable, Jeff Jones, Farrukh T. Awan

Blood (2023) 142 (Supplement 1): 3142.

https://doi.org/10.1182/blood-2023-181239

Published: 2023

Journal Articles

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell–engaging antibody AMG 330

Christina Krupka, Peter Kufer, Roman Kischel, Gerhard Zugmaier, Jan Bögeholz, Thomas Köhnke, Felix S. Lichtenegger, Stephanie Schneider, Klaus H. Metzeler, Michael Fiegl, Karsten Spiekermann, Patrick A. Baeuerle, Wolfgang Hiddemann, Gert Riethmüller, Marion Subklewe

Blood (2014) 123 (3): 356–365.

https://doi.org/10.1182/blood-2013-08-523548

Published: 2014

Includes: Supplemental data

Journal Articles

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

Blood (2012) 120 (26): 5185–5187.

https://doi.org/10.1182/blood-2012-07-441030

Published: 2012

Journal Articles

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab

Matthias Klinger, Christian Brandl, Gerhard Zugmaier, Youssef Hijazi, Ralf C. Bargou, Max S. Topp, Nicola Gökbuget, Svenja Neumann, Mariele Goebeler, Andreas Viardot, Matthias Stelljes, Monika Brüggemann, Dieter Hoelzer, Evelyn Degenhard, Dirk Nagorsen, Patrick A. Baeuerle, Andreas Wolf, Peter Kufer

Blood (2012) 119 (26): 6226–6233.

https://doi.org/10.1182/blood-2012-01-400515

Published: 2012

Includes: Supplemental data

Journal Articles

Autologous T Cells From AML Patients Can Be Effectively Recruited for In-Vitro Lysis of Blasts by a Novel CD33/CD3-Bispecific BiTE Antibody

Michael Aigner, PhD, Julian Feulner, Roman Kischel, MD, Peter Kufer, MD, Patrick A Baeuerle, PhD, Andreas Mackensen, MD, Stefan W. Krause, MD

Blood (2010) 116 (21): 14.

https://doi.org/10.1182/blood.V116.21.14.14

Published: 2010

Journal Articles

Identification of a Predictive Factor for Reversible Neurological Adverse Events in a Subset of Non-Hodgkin Lymphoma Patients Treated with CD19-Specific BiTE ® Antibody Blinatumomab.

Gerhard Zugmaier, Dirk Nagorsen, Matthias Klinger, Ralf C Bargou, Mariele Goebeler, Andreas Viardot, Patrick A Baeuerle, Peter Kufer

Blood (2009) 114 (22): 4793.

https://doi.org/10.1182/blood.V114.22.4793.4793

Published: 2009

Journal Articles

Transient Laboratory Findings Upon First Dosing with T-Cell Engaging BiTE® Antibody Blinatumomab in Non-Hodgkin Lymphoma Patients.

Dirk Nagorsen, Gerhard Zugmaier, Peter Kufer, Matthias Klinger, Andreas Viardot, Mariele Goebeler, Margit Schmidt, Petra Klappers, Andreas Wolf, Christian Brandl, Patrick A Baeuerle, Ralf C Bargou

Blood (2009) 114 (22): 4798.

https://doi.org/10.1182/blood.V114.22.4798.4798

Published: 2009

Journal Articles

Report of a Phase II Trial of Single-Agent BiTE® Antibody Blinatumomab in Patients with Minimal Residual Disease (MRD) Positive B-Precursor Acute Lymphoblastic Leukemia (ALL).

Blood (2009) 114 (22): 840.

https://doi.org/10.1182/blood.V114.22.840.840

Published: 2009

Journal Articles

Confirmation of Safety, Efficacy and Response Duration in Non-Hodgkin Lymphoma Patients Treated with 60 μg/m 2 /d of BiTE® Antibody Blinatumomab.

Dirk Nagorsen, Gerhard Zugmaier, Andreas Viardot, Mariele Goebeler, Richard Noppeney, Margit Schmidt, Petra Klappers, Patrick A Baeuerle, Peter Kufer, Ralf C Bargou

Blood (2009) 114 (22): 2723.

https://doi.org/10.1182/blood.V114.22.2723.2723

Published: 2009

Journal Articles

Sustained Response Duration Seen after Treatment with Single Agent Blinatumomab (MT103/MEDI-538) in the Ongoing Phase I Study MT103- 104 in Patients with Relapsed NHL

Ralf C Bargou, MD, Peter Kufer, MD, Mariele Goebeler, MD, Stefan Knop, MD, Hermann Einsele, MD, Richard Noppeney, MD, Andreas Viardot, MD, Patrick A Baeuerle, PhD, Carsten Reinhardt, MD, Margit Schmidt, PhD, Petra Klappers, Dirk Nagorsen, MD, Gerhard Zugmaier, MD

Blood (2008) 112 (11): 267.

https://doi.org/10.1182/blood.V112.11.267.267

Published: 2008

Journal Articles

Treatment with Anti-CD19 BiTE Antibody Blinatumomab (MT103 / MEDI-538) Is Able to Eliminate Minimal Residual Disease (MRD) in Patients with B-Precursor Acute Lymphoblastic Leukemia (ALL): First Results of An Ongoing Phase II Study.

Max Topp, MD, Nikola Goekbuget, MD, Peter Kufer, MD, Gerhard Zugmaier, MD, Evelyn Degenhard, Svenja Neumann, MD, Heinz A Horst, MD, Andreas Viardot, MD, Mathias Schmid, MD, Oliver G. Ottmann, MD, Margit Schmidt, PhD, Carsten Reinhardt, MD, Patrick A Baeuerle, PhD, Dirk Nagorsen, MD, Dieter Hoelzer, MD, PhD, Ralf C. Bargou, MD

Blood (2008) 112 (11): 1926.

https://doi.org/10.1182/blood.V112.11.1926.1926

Published: 2008

Journal Articles

Activation of T Cells by Bispecific Single-Chain Construct MT103 (MEDI-538) Is Strictly Target Cell-Dependent.

Klaus Brischwein, Scott A. Hammond, Larissa Parr, Schlereth Bernd, Mathias Locher, Peter Kufer, Patrick A. Baeuerle

Blood (2006) 108 (11): 3889.

https://doi.org/10.1182/blood.V108.11.3889.3889

Published: 2006

NARROW

A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of CLN-978 (CD19XCD3XHSA) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell–engaging antibody AMG 330

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab

Autologous T Cells From AML Patients Can Be Effectively Recruited for In-Vitro Lysis of Blasts by a Novel CD33/CD3-Bispecific BiTE Antibody

Identification of a Predictive Factor for Reversible Neurological Adverse Events in a Subset of Non-Hodgkin Lymphoma Patients Treated with CD19-Specific BiTE ® Antibody Blinatumomab.

Transient Laboratory Findings Upon First Dosing with T-Cell Engaging BiTE® Antibody Blinatumomab in Non-Hodgkin Lymphoma Patients.

Report of a Phase II Trial of Single-Agent BiTE® Antibody Blinatumomab in Patients with Minimal Residual Disease (MRD) Positive B-Precursor Acute Lymphoblastic Leukemia (ALL).

Confirmation of Safety, Efficacy and Response Duration in Non-Hodgkin Lymphoma Patients Treated with 60 μg/m 2 /d of BiTE® Antibody Blinatumomab.

Sustained Response Duration Seen after Treatment with Single Agent Blinatumomab (MT103/MEDI-538) in the Ongoing Phase I Study MT103- 104 in Patients with Relapsed NHL

Treatment with Anti-CD19 BiTE Antibody Blinatumomab (MT103 / MEDI-538) Is Able to Eliminate Minimal Residual Disease (MRD) in Patients with B-Precursor Acute Lymphoblastic Leukemia (ALL): First Results of An Ongoing Phase II Study.

Activation of T Cells by Bispecific Single-Chain Construct MT103 (MEDI-538) Is Strictly Target Cell-Dependent.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only